Ardelyx to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Ardelyx (NASDAQ: ARDX) has announced its participation in three major healthcare investor conferences in March 2025. The company will present at the Leerink Partners 2025 Global Healthcare Conference on March 11 at 8:00 a.m. ET, attend the Jefferies Biotech on the Beach Summit on March 12, and participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference on March 13 at 10:00 a.m. ET.
All events will take place in Miami, FL. Live webcasts of the Leerink presentation and Barclays fireside chat will be available on the Events and Presentations page of the Ardelyx website (ir.ardelyx.com), with replays accessible for 30 days following each event. The company will also conduct one-on-one meetings during all three conferences.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ARDX declined 1.54%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences:
Leerink Partners 2025 Global Healthcare Conference
Location: Miami, FL
Presentation: Tuesday, March 11 at 8:00 a.m. ET
1x1 Meetings: Tuesday, March 11
To access the live webcast of the Leerink presentation, please visit the Events and Presentations page within the Ardelyx website at ir.ardelyx.com. A replay of the presentation will be available on the Ardelyx website for 30 days following the event.
Jefferies Biotech on the Beach Summit
Location: Miami, FL
1x1 Meetings: Wednesday, March 12
Barclays 27th Annual Global Healthcare Conference
Location: Miami, FL
Fireside Chat: Thursday, March 13 at 10:00 a.m. ET
1x1 Meetings: Thursday, March 13
To access the live webcast of the Barclays Fireside Chat, please visit the Events and Presentations page within the Ardelyx website at ir.ardelyx.com. A replay of the fireside chat will be available on the Ardelyx website for 30 days following the event.
About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com
FAQ
When is Ardelyx (ARDX) presenting at the Leerink Partners Conference in 2025?
How can investors access Ardelyx's (ARDX) presentation webcasts from the March 2025 conferences?
Which investor conferences is Ardelyx (ARDX) attending in March 2025?
When is Ardelyx's (ARDX) fireside chat at the Barclays Healthcare Conference?
